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Abstract 
Background: Best vitelliform macular dystrophy (BVMD) is an autosomal dominant macular degeneration. The typi-
cal central yellowish yolk-like lesion usually appears in childhood and gradually worsens. Most cases are caused by 
variants in the BEST1 gene which encodes bestrophin-1, an integral membrane protein found primarily in the retinal 
pigment epithelium.
Methods: Here we describe the spectrum of BEST1 variants identified in a cohort of 57 Italian patients analyzed by 
Sanger sequencing. In 13 cases, the study also included segregation analysis in affected and unaffected relatives. We 
used molecular mechanics to calculate two quantitative parameters related to calcium-activated chloride channel 
(CaCC composed of 5 BEST1 subunits) stability and calcium-dependent activation and related them to the potential 
pathogenicity of individual missense variants detected in the probands.
Results: Thirty-six out of 57 probands (63% positivity) and 16 out of 18 relatives proved positive to genetic testing. 
Family study confirmed the variable penetrance and expressivity of the disease. Six of the 27 genetic variants discov-
ered were novel: p.(Val9Gly), p.(Ser108Arg), p.(Asn179Asp), p.(Trp182Arg), p.(Glu292Gln) and p.(Asn296Lys). All BEST1 
variants were assessed in silico for potential pathogenicity. Our computational structural biology approach based 
on 3D model structure of the CaCC showed that individual amino acid replacements may affect channel shape, 
stability, activation, gating, selectivity and throughput, and possibly also other features, depending on where the 
individual mutated amino acid residues are located in the tertiary structure of BEST1. Statistically significant correla-
tions between mean logMAR best-corrected visual acuity (BCVA), age and modulus of computed BEST1 dimeriza-
tion energies, which reflect variations in the in CaCC stability due to amino acid changes, permitted us to assess the 
pathogenicity of individual BEST1 variants.
Conclusions: Using this computational approach, we designed a method for estimating BCVA progression in 
patients with BEST1 variants.
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Background
Best vitelliform macular dystrophy (BVMD) (OMIM 
#153700), also known as Best’s disease, is an autoso-
mal dominant slowly progressive form of retinal macu-
lar degeneration. The typical central yellowish yolk-like 
lesion due to accumulation of lipofuscin in the retinal 
pigment epithelium (RPE) usually appears in childhood. 
The lesion gradually worsens [1] causing progressive 
macular atrophy or fibrosis and subsequent loss of visual 
acuity [2].
Five stages of the disease have been described: in the 
first or pre-vitelliform stage, usually discovered inciden-
tally, subtle RPE alterations of the macula cause no symp-
toms. The second or vitelliform stage is characterized by 
a well-defined 0.5 to 2 mm diameter “egg-yolk” lesion in 
the macula, and patients may experience symptoms such 
as metamorphopsia, blurred vision and a decrease in vis-
ual acuity. In stage 3, this deposit is partially reabsorbed 
and deposited in a layer in the macula, known as “pseu-
dohypopyon”. In the fourth or vitelliruptive stage, there 
is partial reabsorption of the material (scrambled-egg 
lesion) and macular atrophy. Macular fibrosis develops in 
stage 5 [3].
The vast majority of cases are caused by a variant in the 
BEST1 gene (also known as VMD2) which encodes bes-
trophin-1 (BEST1) [4].
Bestrophin-1 protein is expressed in the basolateral 
membrane of the RPE [4]. It is essential for normal eye 
development during embryogenesis and for retinal home-
ostasis throughout life [5]. Bestrophin-1 belongs to the 
family of calcium-activated chloride channels (CaCCs) 
that regulate the flow of chloride and other monovalent 
anions across cell membranes in response to intracel-
lular  Ca2+ levels [6–8]. These channels occur in various 
types of cell. The mechanisms of CaCC anion selectivity, 
calcium-dependent gating and the bestrophin-1 domains 
involved in channel regulation are not fully understood. 
The X-ray structure of BEST1 from Gallus gallus, which 
shares 74% sequence identity with human BEST1, showed 
that five bestrophin-1 molecules compose a CaCC, which 
contains a single long pore along a five-fold symmetry 
axis (Fig. 1) [9, 10]. The pore extends from the extracel-
lular side across the cell membrane and through the cyto-
sol. Its variable diameter defines two narrow hydrophobic 
regions: the neck and the aperture, which are thought to 
be related to channel gating and anion selectivity [9, 10]. 
The X-ray structure of BEST1 CaCC also shows five cal-
cium-binding sites in the cytosolic portions of the subu-
nits  (Ca2+ clasps) and three binding sites for  Cl− for each 
subunit in the channel pore [9, 10].
The N-terminal region of bestrophin-1 (residues 1–390 
in human BEST1) is highly conserved in eukaryotic 
CaCCs and has been shown sufficient for CaCC activ-
ity and  Cl− ion transport [11]. The C-terminal cytosolic 
portion of the protein (amino acids 391–585) is predicted 
to be unstructured with an as yet undefined role in chan-
nel regulation [10]. A water molecule, acidic residues 
Asp301, Asp304 and backbone carbonyl groups of two 
neighboring bestrophin-1 subunits cooperate in calcium 
ion coordination in the  Ca2+ clasps [9, 10], Fig. 2.
Fig. 1 X-ray structure of bestrophin-1 from Gallus gallus [9, 10] forming a calcium-activated chloride transmembrane channel (CaCC) composed 
of five identical subunits and containing a single long pore along the axis of symmetry. a Top view (extracellular side), b side view, c bottom view 
(cytosol side, channel aperture). The CaCC is shown in Corey–Pauling–Koltun (CPK) representation, dark green spheres—chloride ions (A), orange 
spheres—potassium ions (not visible), blue spheres—calcium ions (not visible)
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Most of the approximatively 200 known disease-caus-
ing variants in BEST1 associated with retinal degen-
erative disorders have been reported to induce CaCC 
aberrations [5, 12–15]. Alterations in BEST1 CaCC func-
tions lead to a diminished electrooculogram (EOG) light 
peak to dark trough ratio typical of BVMD [16]. BVMD is 
a heterogeneous pleomorphic disease underling different 
phenotypes and with alternative modes of inheritance. 
Although most cases show autosomal dominant inher-
itance, recessive inheritance has also been described [7, 
9, 10]. Patients with recessive inheritance may have the 
classic features of Best disease [17], including a central 
vitelliform lesion, or may have extramacular punctate 
flecks without any notable central lesion [18]. Variants 
in BEST1 are also responsible for other clinically dis-
tinct human diseases: autosomal dominant vitreoretino-
choroidopathy (ADVIRC) (OMIM #193220), autosomal 
recessive bestrophinopathy (ARB) (OMIM #611809) and 
retinitis pigmentosa (RP) (OMIM #613194) [19].
Here we report the results of the characterization of 
BEST1 variants in an Italian population consisting of 
57 probands and 13 families, thus contributing to the 
molecular epidemiology of Best disease in our country. 
Six of the 27 BEST1 variants detected are novel.
All variants were assessed by computational structural 
biology. The conclusions of computational modelling 
led to the formulation of simple approximate quantita-
tive structure-pathogenicity relationships (QSPR) of the 
BEST1 variants and a tool for predicting visual acuity 
progression in individuals with inherited BEST1 variants.
Methods
Genetic testing
Fifty-seven probands with clinical features suggesting 
Best’s disease were examined in different eye clinics and 
hospitals. Most of the patients underwent complete oph-
thalmic examination, including logMAR best-corrected 
visual acuity (BCVA), anterior and posterior segment 
examination and retinal imaging. Imaging included fun-
dus photography (Zeiss, Visucam, Oberkochen, Ger-
many), spectral domain optical coherence tomography 
(SD-OCT, Spectralis HRA + OCT, Heidelberg Engineer-
ing, Heidelberg, Germany), infra-red (IR) imaging and 
blue fundus autofluorescence (B-FAF) (Spectralis HRA 
and HRA II, Heidelberg Engineering). Some patients also 
underwent electrophysiological testing including elec-
tro-oculogram and multifocal electroretinogram [EOG, 
mfERG, VERIS Clinic 4.9, Electro-Diagnostic Imaging, 
San Mateo, CA and Retimax instrument (CSO, Firenze, 
Italy)] recordings and ultra-structural morphology evalu-
ation by adaptive optics (AO, rtx1, Imagine Eyes, Orsay, 
France) retinal imaging. A small number of patients were 
only addressed to our laboratories for genetic testing 
from different institutions, therefore with partial clinical 
data.
A genetic test was performed to confirm the diagnosis 
of Best disease; whenever possible, ophthalmic examina-
tion and genetic analysis were extended to members of 
the proband’s family.
A total of 57 blood samples from patients and 18 from 
family members were received and analyzed by MAGI 
Laboratory (MAGI’s Lab, Rovereto, Italy). DNA was 
extracted by commercial kit (Blood DNA Kit E.Z.N.A.; 
Omega Bio-Tek Inc., Norcross, GA, USA). Extracted 
DNA underwent polymerase chain reaction (PCR) to 
amplify all coding regions (exons 2–11) and the intron/
exon junctions of BEST1 (NM_004183.3). The products 
were purified and sequenced with a Beckman Coulter 
CEQ  8000 sequencer (Beckmann Coulter, Milan, Italy). 
All laboratory protocols are available upon request.
The electropherograms of all amplified fragments were 
analyzed with ChromasPro 1.5 software (Technelysium 
Pty Ltd, Australia; http://techn elysi um.com.au) and then 
compared with the reference sequences using Basic Local 
Alignment Search Tool 2 (BLAST2) sequences (http://
blast .ncbi.nlm.nih.gov).
Fig. 2 Crystal structure of the “Ca2+ clasp” of BEST1 from Gallus 
gallus [9, 10]. The calcium binding site is formed by two bestrophin-1 
subunits represented by the red (subunit A) and blue ribbons 
(subunit B) and is involved in the CaCC activation.  Ca2+ is shown as 
a dark blue sphere. Yellow lines indicate calcium ion coordination by 
residues side chains and backbone carbonyl groups of both subunits. 
A water molecule coordinating the calcium ion in the crystal 
structure is not shown
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For the identification of variants, the Retina Interna-
tional database (http://www.retin a-inter natio nal.org), the 
Human Gene Mutation Database Professional version 
2017.2 (https ://porta l.bioba se-inter natio nal.com/hgmd/
pro/), the Exome Variant Server (http://evs.gs.washi 
ngton .edu/EVS/) and dbSNP (https ://www.ncbi.nlm.nih.
gov/snp/) were also consulted.
New variants were analyzed for their putative patho-
genicity using three on-line softwares: Polyphen 2 (Poly-
morphism Phenotyping v2; http://genet ics.bwh.harva 
rd.edu/pph2), SIFT (Sorting Intolerant From Tolerant; 
http://sift.bii.a-star.edu.sg/) and Mutation Taster (http://
mutat ionta ster.org/). Pedigrees were designed accord-
ing to Bennett et  al. [20] using HaploPainter software 
(http://haplo paint er.sourc eforg e.net/). New variants were 
classified according to the American College of Medical 
Genetics and Genomics standards and guidelines [21].
Molecular modelling
A refined 3D template model of human CaCC was pre-
pared from the X-ray structure of chicken BEST1 (PDB 
entries 4RDQ and 5T5 N, 409 residues, resolution 3.1 
Å) [9, 10] by protein homology modelling and molecu-
lar geometry optimization. Amino acid sequences of the 
N-terminal domain of Homo sapiens bestrophin-1 (Uni-
ProtKB O76090, residues 1-366) and of bestrophin-1 
from Gallus gallus were aligned by the EMBOSS Needle 
sequence alignment server (73.6% identity, 88.3% similar-
ity, gaps 0.5%) (https ://www.ebi.ac.uk/Tools /psa/embos 
s_needl e/). The 3D homology model of human bestro-
phin-1 channel subunit A was built by comparative mod-
elling from the chicken CaCC template structure with the 
help of the Prime protein structure prediction approach 
[22] using standard parameters (Schrödinger, LLC, New 
York, 2014). The loops of the human bestrophin-1 model 
were perfected using the refine loops tool of Prime. The 
homology model was inspected with help of Prime to 
ensure that there was no violation of protein stereo-
chemistry. The human BEST1 model contained one  Ca2+ 
cation, two  K+, three  Cl− and one water molecule coor-
dinating the calcium ion. After building the 3D model 
of BEST1 protein, five protein subunits were superim-
posed on the chicken CaCC template structure using 
the Prime structural alignment module (Schrödinger, 
LLC, New York, 2014) to obtain the quaternary struc-
ture of the human chloride channel. A dimer formed 
by two BEST1 subunits was separated from the CaCC 
model and further refined to convergence by energy-
minimization using molecular mechanics (MM). During 
minimization, the OPLS-2005 force field [23–25] and the 
generalized Born implicit solvation model (GB/SA) [26] 
were employed with MacroModel software (Schrödinger 
LLC, New York, NY, 2014). At first, the protein backbone 
atoms and all ions were constrained in their initial posi-
tions, while all other atoms were unrestrained. In the 
final minimization step, all atoms were set free to find 
their relaxed positions in the model structure of human 
bestrophin-1 subunits.
To study the effect of individual variants detected in 
probands, residue replacement with optimal side chain 
rotamer selection were conducted in the BEST1 dimer 
using MacroModel, followed by extensive dimer and 
monomer structure minimization. The consequence of 
variants for the bestrophin-1 subunit binding to form 
the pentameric channel and of subunit binding capacity 
to  Ca2+ ions needed for channel regulation were esti-
mated with the help of relative dimerization and calcium 
binding energies (ΔΔEdim and ΔΔECabin) computed with 
respect to the native BEST1 protein. The ΔΔEdim energy 
estimates the extent of possible damage or change in 
CaCC formation, expressed as the change in binding 
energy between neighboring bestrophin-1 subunits A 
and B in CaCC, caused by a variant (var), as compared to 
the reference native BEST1 [27–29]:
where  Etot{Z}aq is the total molecular mechanics (MM) 
energy of hydrated {}aq protein Z (dimer AB or mono-
mers A and B) computed by MacroModel (Schrödinger 
LLC, New York, NY, 2014). The relative  Ca2+ binding 
energy (ΔΔECabin) reflects the extent of possible damage 
or change to channel regulation expressed as the altered 
ability of the BEST1 dimer AB to bind calcium ions due 
to a variant, with respect to the reference native BEST1:
where  Etot{Z}aq and  Esol{Ca2+}aq are the total MM energy 
of the hydrated bestrophin-1 dimer with or without 
bound calcium ions, or the solvation energy of the  Ca2+ 
ion.
(1)
!!Edim =!Edim
{
BEST1var,AB
}
aq
−!Edim
{
BEST1native,AB
}
aq
(2)
!Edim
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}
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}
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}
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]
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QSPR of BEST1 variants affecting the visual acuity of 
the probands were elaborated with help of the  Cerius2 
software package  (Cerius2 Life Sciences, version 4.5, 
2000. Accelrys, San Diego, CA, USA) [30, 31]. Clini-
cally evaluated stages and visual acuities averaged over 
both eyes of a proband and averaged over probands car-
rying the same BEST1 variant were correlated by linear 
regression with the computed subunit dimerization and 
calcium binding energies (ΔΔEdim, ΔΔECabin) as well as 
the modulus (absolute value) of dimerization energy, 
|ΔΔEdim|. Due to the lack of other functional parameters 
such as the Arden Index or Mf-ERG for all the patients 
other correlations were not possible. A set of 20 distinct 
BEST1 variants in 27 probands, for whom BCVA data 
was available (Table 1), was entered in the QSPR model. 
Statistical techniques for validation of the regression 
(leave-one-out cross-validation) were used to identify 
outliers (data points modelled poorly by the regres-
sion equation). In the  Cerius2, an outlier is defined as a 
data point with a residual more than twice the standard 
deviation of the residuals generated in the validation 
procedure.
Results
Genotype
The subjects of the study were 30 males and 27 females 
(mean age ± SD 40.7 ± 18.6 years; range 9-85) with clini-
cal features suggesting Best’s disease. Genetic testing 
revealed 26 different variants in 36 patients who tested 
positive (63% positivity); 20 variants are already known to 
be associated with Best disease, and six were novel and 
associated with BVMD for the first time (Table 1). One 
of the six new variants regards a nucleotide substitution 
that causes an amino acid change already established as 
pathogenic, and we therefore do not discuss it here. We 
describe the clinical features of probands carrying the 
other five new variants in Additional files 1, 2.
Some family members of 13 patients testing positive for 
a variant in BEST1 were also studied by target sequenc-
ing: 16 out of 18 carried a variant in BEST1, eight of 
whom were clinically healthy and eight affected (Fig. 3). 
Penetrance in our families was estimated at 72.4% with 
no sex differences (71.4% and 73.3% for females and 
males, respectively).
Extension of study to family members was only possi-
ble for 2 out of 6 new variants: p.(Val9Gly) found in the 
asymptomatic father of proband 3, and p.(Asn296Lys) 
found in the affected father and grandmother of proband 
31 (Fig. 3).
Pathogenic BEST1 variants were scattered throughout 
the gene (Fig. 4).
Structural biology of BEST1 variants
A variant can affect the structure and function of BEST1 
CaCC in a number of ways. Depending on its site in bes-
trophin-1 molecular structure, an amino acid replace-
ment can lead to: (i) altered  Ca2+ binding and defective 
channel activation; (ii) conformational changes affecting 
channel gating; (iii) anomalous binding between bes-
trophin-1 subunits and modified channel stability; (iv) 
variations in channel pore size and shape and altered 
ion throughput rate or specificity; and (v) other changes 
(Fig. 5). We studied structural changes linked to the 36 
variants (Table 2) in a 3D model of human bestrophin-1 
prepared by comparative modelling from the crystal 
structure of chicken BEST1 [9, 10]. The locations of the 
amino acid variants in the 3D structure of bestrophin-1 
of the probands are shown in Fig. 6.
Besides locating variant residues, we used molecular 
mechanics to calculate the relative energies of dimeriza-
tion (ΔΔEdim, Eqs. 1 and 2) of two bestrophin-1 subunits 
bearing a variant. The dimerization energies approximate 
the probability that assembled bestrophin-1 variants 
display an alteration of the ideal quaternary structure of 
CaCC affecting its function. We also computed relative 
energies of calcium binding (ΔΔECabin, Eqs. 3 and 4) by 
the variant bestrophin-1 subunits as an approximation 
of the possibility of altered calcium-dependent regula-
tion of CaCC for all the variants detected in the probands 
(Table  2). The relative energies therefore characterize 
deviation from native bestrophin-1 structure and/or 
function, presumably reflecting potential pathogenicity.
To explore the possibility of a link between the com-
puted energies (ΔΔEdim, ΔΔECabin and |ΔΔEdim|) and clin-
ical symptoms of probands with the BEST1 variants in 
question, we established a QSPR [29]. In the QSPR model 
we used the age-adjusted mean Best’s Disease Sever-
ity Index (BDSI), averaged over all N probands with the 
same variant, to represent the severity of observed clini-
cal symptoms on a quantitative scale (0% to 100%):
The summation in Eq.  (5) includes probands with the 
same variant, where  logMARLE,i and  logMARRE,i are left 
(LE) and right eye (RE) best-corrected visual acuities 
(BCVA) of probands in the log Minimum Angle of Reso-
lution scale (logMAR—Table  1) determined by clinical 
evaluation. In Eq.  (5), the sum of BCVA was normalized 
by a factor of 2.6 to express loss of vision as a percentage 
(logMAR = 0/0 means perfect vision of LE/RE, while log-
MAR ≥ 1.3/1.3 means complete blindness of both eyes). 
In Eq.  (5),  Ai is the age of proband i at the time of clini-
cal evaluation and the corresponding time factor of the 
(5)
BDSI =
1
N
N∑
i
[
logMARLE,i + logMARRE,i
2.6
· 100% · e−
Ai
100
]
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BDSI: f = e−
Ai
100 adjusts the severity index for age of dis-
ease onset ( f ∼= 1 for a patient diagnosed at age Ai = 1 year 
while f ∼= 0.368 for a patient diagnosed with BVMD at 
age Ai = 100 years). BDSI = 0% means perfect vision (no 
symptoms), BDSI = 100% means complete loss of vision. 
See legend of Table 2 for examples of BDSI index values in 
relation to BCVA and age of proband. The BDSI was ana-
lyzed for correlations with computed energies (ΔΔEdim, 
Fig. 3 Pedigrees of 13 probands with Best disease. P, proband; E−, negative to genetic test; square, male subject; circle, female subject; black 
symbol, affected subject; white symbol, healthy subject; * documented clinical evaluation; ● obligate carrier; yr, age in years; maternal and paternal 
alleles are identified by square brackets; =, indicates no change in the second protein allele
Fig. 4 Distribution of BEST1 variants found in our patients. Graphical representation of the distribution of BEST1 variants throughout the gene. New 
variants are shown in rectangular boxes
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ΔΔECabin) and with |ΔΔEdim|. The modulus of dimerization 
energy was used in the QSPR models because we assumed 
that elevated and low relative energies of bestrophin-1 
subunit dimerization could both be harmful to the normal 
structure and function of the CaCC.
We managed to establish a statistically significant QSPR 
model correlating BDSI with the modulus of computed rel-
ative dimerization energy:
(for details see Fig. 7) and linking structural biology con-
siderations to the clinical findings. This validated QSPR 
model also enables prediction of clinical symptoms (pre-
dicted mean visual acuity averaged over both eyes at a 
given patient age, PMVA or  logMARave) of other similar 
BEST1 variants and estimation of the pathogenicity of 
BEST1 variants based on |ΔΔEdim| computed for a given 
variant by molecular mechanics:
(6)BDSI = 0.24935 · |!!Edim| + 6.56527
(7)
PMVA =logMARave =
2.6
200
· [0.24935 · |!!Edim| + 6.56527] · e
A
100
where A is the age of the patient (set at 40  years in 
our predictions, Table  2). In the logMAR scale (0 to 
1.3 or more) higher values mean worse visual func-
tion, so that BEST1 variants leading to predicted 
 logMARave values higher than 0.5 (corresponding to 
|ΔΔEdim| ≥ 77 kcal mol−1) can be classified as potentially 
pathogenic. Calculated  logMARave values lower than 0.5 
are regarded as less likely to be pathogenic (Table 2). The 
threshold 0.5 is based on the WHO criteria for low vision 
using the logMAR scale [31].
Finally, out of the six new BEST1 variants reported 
here, four residue replacements [p.(Val9Gly), 
p.(Asn179Asp), p.(Glu292Gln) and p.(Asn296Lys)] 
seem to affect  Ca2+ ion binding and CaCC activation 
(Table 2).
Discussion
Computational modelling of the tertiary structure of 
bestrophin-1 and quaternary structure of CaCC made 
it possible to link the detected variants to possible 
molecular mechanisms that may be involved in chan-
nel function impairment. In relation to the location of 
individual amino acid replacements in the 3D structure 
of bestrophin-1, the variants may affect channel shape, 
stability, activation, gating, ion selectivity, ion through-
put, and probably other features as well. Our computa-
tional structural biology approach was therefore based 
on characteristics involving protein structure and func-
tion which are more complex than similarity/diversity 
of variant amino acid residues.
It is complicated to quantify the clinical features of 
probands with Best vitelliform macular dystrophy. Best 
disease stages of the left and right eye as diagnosed in 
our probands were not correlated with BCVA in the 
logMAR scale (Table 1). We, therefore, selected BCVA 
and designed our own age-adjusted quantitative Best’s 
disease severity index (BDSI), see Eq.  5. The BDSI 
index showed a good correlation with the computed 
modulus of bestrophin-1 subunit dimerization energy 
|ΔΔEdim| (Fig. 7) which is assumed to reflect the poten-
tial harmful effect of individual missense variants on 
BEST1 CaCC structure and function. During regression 
analysis, it was necessary to remove five outlier points 
(probands P13, P24, P25, P27 and P31) identified by the 
leave-one-out cross-validation algorithm. The corre-
sponding point variants (p.(Tyr29Cys), p.(Arg218Ser), 
p.(Ile232Asn), p.(Ala243Thr) and p.(Glu292Gln) are 
mainly residue replacements leading to low-to-medium 
positive and negative ΔΔEdim values, which are thus 
expected to be linked to small changes in CaCC struc-
ture and function. We can therefore assume that the 
QSPR model and the proposed computational tool for 
Fig. 5 Subunits C and E of the X-ray structure of chicken 
bestrophin-1 (in ribbon representation) forming part of the 
calcium-activated chloride channel [9, 10]. The axial cross-section of 
the ion pore (yellow tube) shows the approximate size and shape of 
the pore and indicates the positions of the pore neck and aperture as 
well as calcium binding sites involved in channel gating. Boundaries 
of the cell membrane are indicated by the horizontal red lines (figure 
adapted from: Ref. [10])
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Fig. 6 3D model of subunit A of human bestrophin-1 (residues 1-366; CPK representation) prepared by homology modelling and relaxed by 
geometrical optimization in water by molecular mechanics from crystal structure of chicken BEST1 [9, 10].  Ca2+ and  K+ ions of neighbouring 
subunit B in the chloride channel coordinated by the C-terminal domain residues of subunit A are marked with (B). The locations of individual 
variant amino acids identified in the probands (Table 1) are shown in purple. a Front view of subunit A with “tail” wrapped around subunit 
B (channel pore inner side). b Side view (binding site to neighbouring subunit E). c Rear view (membrane side). d Side view (binding site to 
neighbouring subunit B)
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BEST1 variant pathogenicity prediction apply to con-
servative as well as radical variants. Although many 
intrinsic factors are known to co-determine the bio-
logical consequences of gene diversity and the resulting 
impairment of health or well-being [32], we were able 
to establish a robust but simple QSPR model linking 
computed relative energies of human bestrophin-1 pro-
tein with the symptoms of BVMD diagnosed in a cohort 
of patients. To illustrate application of the model we 
compare the PMVA of two probands, P4 and P17, of 
similar age bearing different BEST1 variants and dis-
playing different clinical symptoms (Table 3). As we can 
see, patient P17 has greater visual impairment (higher 
 logMARave and mean BDSI values). Structural biology 
assessment of his BEST1 variant predicts larger altera-
tions of stability and structure of assembled bestro-
phin-1 subunits (larger |ΔΔEdim|), possibly detrimental 
to CaCC function. Consequently, predicted mean vis-
ual acuity (PMVA) estimated for P17 at age 40 years is 
larger than the threshold of 0.5 (PMVA = 0.59) and the 
corresponding BEST1 variant p.(Ser108Arg) can thus 
be considered likely pathogenic.
Further calibration of this computational pathogenic-
ity estimate on a much larger cohort of patients and 
wider range of amino acid variants is still needed to set 
the borderline between low and high pathogenicity and 
confirm the reliability of the resulting clinical outcome 
predictions.
Conclusions
Similar computational biology approaches based on 
molecular mechanics energies or other structural prop-
erties of native and variant proteins and their interac-
tions suggest the possibility of exploring the molecular 
basis of genetic diseases and perhaps predicting likely 
clinical outcomes of genetic variants. Worth to note, 
the predicted pathogenicity descriptor PMVA can also 
be used for estimating the development of patient’s 
BCVA over the years by substituting selected age (A) 
into Eq. (7).
We also reported the results of genetic testing in 57 
Italian BVMD patients, including 36 subjects with a 
BEST1 variant. Compared with other reports in the lit-
erature for different populations, our results indicate 
that there are no specific ethnic variants [2], while seg-
regation study confirmed the variable penetrance and 
expressivity of the disease in patients with the same 
BEST1 variant, even in the same family [33, 34]. Six 
new variants are also reported, thus broadening the 
BEST1 variant spectrum.
Fig. 7 Plot of regression equation of Best Disease Severity Index 
(BDSI) versus modulus of relative energy of dimerization |∆∆Edim| of 
variant BEST1 subunits: BDSI = 0.24935 · |∆∆Edim| + 6.56527, Eq. (6). 
BDSI was derived from clinically evaluated BCVA (best-corrected 
visual acuity in logMAR scale) and age of 27 probands, Eq. (5), Table 2; 
∆∆Edim was computed by molecular mechanics from the 3D model 
of human CaCC. Statistical parameters of the correlation: number 
of available data points: n = 20, squared correlation coefficient: 
 R2 = 0.854, leave-one-out cross-validated correlation coefficient: 
R
2
xv = 0.827, Fischer F-test: F = 76.164, significance of correlation: 
α > 95%, number of outliers removed:  no = 5
Table 3 Comparison of two BEST1 variants
a Age of proband at last clinical evaluation
b BCVA (best-corrected visual acuity) in logMAR scale of left (LE) and right eye (RE)
c Average BCVA value  (logMARLE + logMARRE)/2
d Mean age-adjusted Best’s Disease Severity Index
e Modulus of computed relative energy of variant BEST1 subunit dimerization
f PMVA—predicted mean visual acuity  (logMARLE + logMARRE)/2 of an individual with a given bestrophin-1 variant at age 40 years
Proband ID BEST1 variant Agea [years] BCVAbLE BCVA
b
RE logMAR
c
ave Mean  BDSI
d [%] |ΔΔEdim|
e 
[kcal mol−1]
PMVAf Estimated 
BEST1 variant 
pathogenicity
P4 p.(Vla9Gly) 27 0.0 0.6 0.30 17.6 34 0.29 Likely non-pathogenic
P17 p.(Ser108Arg) 26 0.1 1.0 0.55 32.6 96 0.59 Likely pathogenic
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Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1296 7-019-2080-3.
 Additional file 1. Clinical findings for patient P4, P17, P18, P19 and P31 
Additional file 2. Figure S1-P4: Right eye five-year follow-up in a 
22-year-old patient carrying a p.Val9Gly variant in BEST1. SD-OCT scans 
and corresponding FAF through the fovea and vitelliform deposit at 
baseline (A, B and C) and 5 years later (D, E and F). After 5 years the patient 
showed a “vitelliruptive” stage with irregular FAF signal (D), elongation of 
the outer segments under the fovea (E) and a thin neurosensory retinal 
detachment surrounding the lipofuscin deposit (E, F). Fundus photograph 
of the posterior pole at the last follow-up (G). Figure S2-P4: Left eye 
five-year follow-up of the same patient. At baseline a “pseudohypopyon” 
stage is clearly visible in FAF (A) and OCT scans (B, C). Serous detachment 
of the neurosensory retina is visible in the upper macula with decreased 
FAF levels (Fig. 2B). In the bottom row of images, the yellow vitelliform 
material is evident by FAF. Five years later, there was reduction of the 
serous detachment and contraction of the deposit (“vitelliruptive” stage). 
Irregular FAF signal (D), preserved elongation of photoreceptors (E, F) and 
fundus photograph of posterior pole in “vitelliruptive” stage (G). Figure 
S3-P17: FAF images of Best’s maculopathy patient (P17) (A), showing a 
lesion consisting of a circular hyperautofluorescent parafoveal circle with 
an annular hypofluorescent ring enclosing a second inner hyperautofluo-
rescent ring and a hypoautofluorescent central spot (tip of the dome). The 
infrared images show hyperreflective foveal changes more visible in the 
LE (B bottom). The corresponding SD-OCT scans in both eyes (C) show 
subfoveal hyperreflective lipofuscin deposits at RPE level, surrounded by 
thin neurosensory retinal detachment, more prominent in the LE. The 
photoreceptor layer, partially intact in the RE and with slight disruption in 
the LE, is displaced on top of the lesion. In the LE tiny microcystic spaces 
subtending inner-layer retinal splitting can also be observed. Figure 
S4-P18: FAF (A, C) and OCT scans (B, D) of a 46-year-old patient carrying 
a p.Asn179Asp variant in BEST1. Idiopathic choroidal folds and central 
accumulation of hyperautofluorescent lipofuscin is evident in both eyes. 
The right eye is in “pseudohypopyon” stage, as suggested by the neuro-
sensory retinal detachment, while the left eye is still in “vitelliform” stage. 
Figure S5-P19: FAF and OCT scans of a 13-year-old girl with a Trp182Arg 
variant in BEST1, showing bilateral vitelliform lesions at pseudohypopyon 
stage in both eyes. OCT scans show subfoveal hyperreflective lipofuscin 
deposits at RPE level, surrounded by thin neurosensory retinal detach-
ment. Figure S6-P31: Patient 31 (P31), a 9-year-old boy, showing fundus 
ophthalmoscope evidence of bilateral circular yellowish yolk-like lesions in 
the macular area (D). The lesions are symmetrically hyperautofluorescent 
with a nasal hypoautofluorescent sickle visible by FAF (A). At the same 
location in IR images, there is a circular area of hyporeflectivity matching 
the lipofuscin deposit at sub-RPE level with consequent reorganization of 
the IS-OS junction layer on top of the dome, as seen also in OCT scans (C). 
Preservation of the photoreceptor layer is also confirmed by adaptive opti-
cal images, showing cone mosaic structure in the RE (E), where the lesion 
appears elevated but with a normal arrangement of cones on top of it. In 
fact, intact bright cones can be seen across the central 6 degree eccentric-
ity around the fovea, as well as a circular dark ring of shadow delineating 
the contour line of the lesion, where faint, still resolvable cones seem 
mechanically distorted.
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